Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.

Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.

In today's episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA. ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy. The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy. This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend. In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed. To learn more about ATMA, visit: https://www.atmajourney.com/ To learn more about Catalyst, visit: https://catalystpresents.ca/ #psychedelics #therapy #magicmushrooms